S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
MBRX · Moleculin Biotech, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Moleculin Biotech Inc (MBRX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$6.26
+0.12
(+2.04%)
● At close: October 21 at 4:00:00 PM EDT
$6.06
-0.25
(-3.96%)
Overnight:
11:46:13 PM EDT
DAY'S RANGE
$6.26
$6.26
$6.28
52-WEEK RANGE
$6.26
$3.23
$315.00
What's happening
- MBRX is up 2.04% today, trading at $6.26. — Live quote
- It's trading within 3% of its 52-week low ($3.23). (Finnhub fundamentals)
- Volume today (671) is well below its 3-month average of 61,670. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.40 actual vs. $-1.58 estimated (+11.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MBRX
-90.65%
vs S&P 500
-103.43%
1-YEAR RETURN
MBRX
-97.55%
vs S&P 500
-112.11%
6-MONTH RETURN
MBRX
-87.10%
3-MONTH RETURN
MBRX
-85.60%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.40
Est. $-1.58
BEAT +11.6%
2026-04-26 (Q1 2026)
$-3.54
Est. $-1.70
MISS -108.7%
2026-01-26 (Q4 2025)
$13.04
Est. $-6.24
BEAT +309.1%
2025-10-26 (Q3 2025)
$-17.00
Est. $-4.97
MISS -241.9%
Valuation Measures & Ratios
Enterprise Value4-$1.9M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.70
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-35.39%
Return on Assets (ROA9)-139.55%
Avg Volume (3M)61,670
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short204,583
Change from Prior Settlement-28.87%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -97.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MBRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$7.6M | -$7.9M | -$5.9M | -$5.7M | -$5.9M | -$7.1M | -$6.2M | -$6.7M |
| Net income | -$7.6M | -$12.8M | -$25.4M | -$17.8M | -$5.9M | -$7.0M | -$6.0M | -$6.4M |
| EPS (basic) | $-1.40 | $-3.54 | $-0.68 | $-28.68 | $-15.80 | $-1.89 | $-2.37 | $-2.61 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | May '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $21.1M | $23.4M | $22.1M | $20.4M | $21.6M | — | $21.0M | $16.9M |
| Total liabilities | $9.5M | $8.2M | $7.1M | $47.3M | $25.2M | — | $7.2M | $5.7M |
| Stockholders' equity | $11.6M | $15.2M | $15.0M | -$26.9M | -$3.6K | — | $13.8M | $11.2M |
| Total current assets | $8.7M | $11.0M | $9.7M | $7.9M | $9.1M | — | $9.3M | $5.2M |
| Total current liabilities | $9.3M | $8.0M | $6.9M | $5.7M | $7.9M | — | $6.9M | $5.4M |
| Cash & equivalents | $7.3M | $10.3M | $8.9M | $6.7M | $7.6M | — | $7.7M | $4.3M |
| Accounts receivable | $4.0K | $9.0K | $7.0K | $2.0K | $1.0K | — | $2.0K | $20.0K |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $62.0K | $70.0K | $78.0K | $77.0K | $99.0K | — | $127.0K | $159.0K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | — | $0 |
| Accounts payable | $4.3M | $4.6M | $3.5M | $2.1M | $3.7M | — | $2.7M | $2.0M |
| Accrued liabilities | $5.0M | $3.4M | $3.3M | $3.6M | $4.2M | — | $4.2M | $3.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $7.0K | $5.0K | $3.0K | $49.0K | $30.0K | — | $14.0K | $0 |
| Retained earnings | -$226.5M | -$218.8M | -$206.0M | -$221.6M | -$196.2M | — | -$178.3M | -$172.4M |
| Accumulated other comprehensive income (loss) | -$64.0K | -$52.0K | $10.0K | — | — | — | — | -$41.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.7M | -$6.1M | -$5.4M | -$7.2M | -$5.6M | -$4.6M | -$5.1M | -$6.1M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $3.6M | $7.6M | $7.5M | $6.4M | $5.4M | $8.0M | $1.0K | $4.7M |
| Free cash flow | — | — | -$5.4M | -$7.2M | -$5.6M | -$4.6M | -$5.1M | -$6.1M |
| Capital expenditures | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Depreciation & amortization | $8.0K | $8.0K | $59.0K | $21.0K | $29.0K | $31.0K | $94.0K | $31.0K |
| Share-based compensation | $436.0K | $380.0K | $459.0K | $303.0K | $417.0K | $485.0K | $427.0K | $353.0K |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts payable | -$238.0K | $1.1M | $1.3M | -$1.5M | $850.0K | $676.0K | -$520.0K | -$283.0K |
| Tax withholding on stock comp | — | — | $8.0K | $0 | $0 | — | $0 | $1.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M | -$15.9M |
| EPS (basic) | $-28.42 | $-189.14 | $-15.07 | $-15.22 | $-0.59 |
Balance sheet
| Line item | Dec '25 | May '25 | Dec '24 | Jan '24 | Dec '23 |
|---|---|---|---|---|---|
| Total assets | $22.1M | — | $16.9M | — | $38.2M |
| Total liabilities | $7.1M | — | $5.7M | — | $12.1M |
| Stockholders' equity | $15.0M | — | $11.2M | — | $30.9M |
| Total current assets | $9.7M | — | $5.2M | — | $26.3M |
| Total current liabilities | $6.9M | — | $5.4M | — | $6.8M |
| Cash & equivalents | $8.9M | — | $4.3M | — | $23.6M |
| Accounts receivable | $7.0K | — | $20.0K | — | $95.0K |
| Property, plant & equipment | $78.0K | — | $159.0K | — | $272.0K |
| Other non-current assets | $900.0K | $900.0K | $0 | — | — |
| Accounts payable | $3.5M | — | $2.0M | — | $2.5M |
| Accrued liabilities | $3.3M | — | $3.3M | — | $4.3M |
| Common stock & paid-in capital | $3.0K | — | $0 | — | $33.0K |
| Retained earnings | -$206.0M | — | -$172.4M | -$146.4M | -$131.6M |
| Accumulated other comprehensive income (loss) | $10.0K | — | -$41.0K | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M |
| Investing cash flow | $0 | -$13.0K | -$124.0K | -$67.0K | -$19.0K |
| Financing cash flow | $27.3M | $4.6M | $4.1M | -$23.0K | $74.7M |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M |
| Capital expenditures | $0 | $13.0K | $124.0K | $67.0K | $19.0K |
| Depreciation & amortization | $90.0K | $126.0K | $127.0K | $130.0K | $164.0K |
| Share-based compensation | $1.7M | $1.7M | $2.0M | $2.3M | $2.4M |
| Deferred income taxes | — | $0 | $0 | $0 | $0 |
| Change in accounts payable | $1.3M | -$468.0K | $403.0K | $731.0K | $235.0K |
| Tax withholding on stock comp | $8.0K | $26.0K | $25.0K | $23.0K | $23.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MBRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-16 to 2026-10-15
Recent transactions
- Insiders have net bought 999,999 shares over the last 182 days, across 3 purchases and 0 sales.
- Most recent: KLEMP WALTER V (CEO and President) — Option exercise of 207,500 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)999,999 sh(3 txns)
Sales (open market)0 sh(0 txns)
Net Shares+999,999
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| KLEMP WALTER V | CEO and President | Option exercise | 2026-10-15 | 207,500 |
| Foster Jonathan P. | Chief Financial Officer | Option exercise | 2026-10-15 | 130,000 |
| PICKER DONALD H | Chief Science Officer | Open market purchase | 2026-08-03 | 173,333 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | KLEMP WALTER V | CEO and President | Option exercise | 207,500 | — |
| 2026-10-15 | KLEMP WALTER V | CEO and President | Tax withholding | 48,659 | $0.37 |
| 2026-10-15 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 130,000 | — |
| 2026-10-15 | Foster Jonathan P. | Chief Financial Officer | Tax withholding | 30,485 | $0.37 |
| 2026-08-03 | Foster Jonathan P. | Chief Financial Officer | Open market purchase | 293,333 | — |
| 2026-08-03 | KLEMP WALTER V | CEO and President | Open market purchase | 533,333 | — |
| 2026-08-03 | PICKER DONALD H | Chief Science Officer | Open market purchase | 173,333 | — |
| 2026-06-22 | PICKER DONALD H | Chief Science Officer | Option exercise | 71 | — |
| 2026-06-22 | PICKER DONALD H | Chief Science Officer | Tax withholding | 21 | $3.12 |
| 2026-06-22 | KLEMP WALTER V | CEO and President | Option exercise | 360 | — |
| 2026-06-22 | KLEMP WALTER V | CEO and President | Tax withholding | 88 | $3.12 |
| 2026-06-22 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 174 | — |
| 2026-06-22 | Foster Jonathan P. | Chief Financial Officer | Tax withholding | 41 | $3.12 |
| 2026-06-20 | PICKER DONALD H | Chief Science Officer | Option exercise | 44 | — |
| 2026-06-20 | PICKER DONALD H | Chief Science Officer | Tax withholding | 13 | $2.88 |
| 2026-06-20 | KLEMP WALTER V | CEO and President | Option exercise | 150 | — |
| 2026-06-20 | KLEMP WALTER V | CEO and President | Tax withholding | 37 | $2.88 |
| 2026-06-20 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 109 | — |
| 2026-06-20 | Foster Jonathan P. | Chief Financial Officer | Tax withholding | 31 | $2.88 |
| 2025-11-04 | PICKER DONALD H | Chief Science Officer | Option exercise | 8,750 | — |
| 2025-11-04 | PICKER DONALD H | Chief Science Officer | Tax withholding | 2,131 | $0.50 |
| 2025-11-04 | KLEMP WALTER V | CEO and President | Option exercise | 28,750 | — |
| 2025-11-04 | KLEMP WALTER V | CEO and President | Tax withholding | 7,001 | $0.50 |
| 2025-11-04 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 20,625 | — |
| 2025-11-04 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 5,023 | $0.50 |
| 2025-06-23 | Foster Jonathan P. | Chief Financial Officer | Open market purchase | 270,270 | $0.37 |
| 2025-06-23 | KLEMP WALTER V | CEO and President | Open market purchase | 675,675 | $0.37 |
| 2025-06-22 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 4,328 | — |
| 2025-06-22 | Foster Jonathan P. | Chief Financial Officer | Tax withholding | 1,054 | $0.27 |
| 2025-06-22 | KLEMP WALTER V | CEO and President | Option exercise | 8,990 | — |
| 2025-06-22 | KLEMP WALTER V | CEO and President | Tax withholding | 2,190 | $0.27 |
| 2025-06-22 | PICKER DONALD H | Chief Science Officer | Option exercise | 1,766 | — |
| 2025-06-22 | PICKER DONALD H | Chief Science Officer | Tax withholding | 430 | $0.27 |
| 2025-06-20 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 2,711 | — |
| 2025-06-20 | Foster Jonathan P. | Chief Financial Officer | Tax withholding | 661 | $0.27 |
| 2025-06-20 | KLEMP WALTER V | CEO and President | Option exercise | 3,750 | — |
| 2025-06-20 | KLEMP WALTER V | CEO and President | Tax withholding | 914 | $0.27 |
| 2025-06-20 | PICKER DONALD H | Chief Science Officer | Option exercise | 1,078 | — |
| 2025-06-20 | PICKER DONALD H | Chief Science Officer | Tax withholding | 263 | $0.27 |
| 2025-06-16 | Foster Jonathan P. | Chief Financial Officer | Option exercise | 833 | — |
| 2025-06-16 | Foster Jonathan P. | Chief Financial Officer | Tax withholding | 203 | $0.69 |
| 2025-06-16 | KLEMP WALTER V | CEO and President | Option exercise | 1,667 | — |
| 2025-06-16 | KLEMP WALTER V | CEO and President | Tax withholding | 406 | $0.69 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:57 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-16 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-16 | 8-K | 2026-10-16 | View on SEC.gov → |
| 2026-10-09 | 8-K | 2026-10-09 | View on SEC.gov → |
| 2026-10-05 | 8-K | 2026-10-05 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-09-25 | 8-K | 2026-09-25 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-18 | 8-K | 2026-09-15 | View on SEC.gov → |
Recent news
Headlines about MBRX (Moleculin Biotech, Inc.). Links open the publisher — we don’t host full articles.
-
Average basic shares outstanding of MOLECULIN BIOTECH INC – GETTEX:A42P30
TradingView · 2026-10-20 -
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Yahoo · 2026-10-20 -
Moleculin Biotech Finalizes 1-for-20 Reverse Stock Split Effective October 20, 2026
Kalkine Media · 2026-10-20 -
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18 -
Moleculin Biotech CEO Walter Klemp Receives 415,000 RSUs and Stock Options on October 15, 2026
Kalkine Media · 2026-10-17 -
415,000 options and an equal stock grant go to Moleculin Biotech (MBRX) CEO Walter V. Klemp.
Stock Titan · 2026-10-17 -
Half of a 250,000-option grant vests on the grant date at Moleculin Biotech (MBRX).
Stock Titan · 2026-10-17 -
Half of the CFO's stock awards vest on grant at Moleculin Biotech (MBRX).
Stock Titan · 2026-10-17
No headlines in this category right now — try “All”.